Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma.
10.3779/j.issn.1009-3419.2021.102.18
- Author:
Yaru HUANG
1
;
Qingwei MENG
1
Author Information
1. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China.
- Publication Type:Journal Article
- Keywords:
Biomarkers;
Immune checkpoint inhibitors;
Immunotherapy;
Malignant pleural mesothelioma;
Tumor heterogeneity
- From:
Chinese Journal of Lung Cancer
2021;24(6):441-446
- CountryChina
- Language:Chinese
-
Abstract:
Malignant pleural mesothelioma (MPM) is a malignant tumor with strong invasiveness, low survival rate and lack of effective treatment options. As the only first-line treatment plan for the advanced MPM, combination of pemetrexed and cisplatin chemotherapy have been existing since the last 20 years. Immunotherapy has long been considered as a potential treatment plan for MPM, mainly including immune checkpoint inhibitors (ICIs), immunotoxin therapy, anti-cancer vaccine and adoptive T-cell therapy. This review focuses on summarizing the current research status of immune checkpoint inhibitors in MPM, discusses the effect of tumor heterogeneity on ICIs treatment, and describes that the biomarker-oriented immunotherapy is a new vision for the realization of individualized treatment of MPM.
.
